| Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab B Lakatos, BG Szabo, I Bobek, L Gopcsa, G Beko, N Kiss-Dala, B Petrik, ... Acta Microbiologica et Immunologica Hungarica 68 (3), 145-152, 2021 | 13 | 2021 |
| Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary BG Szabo, KS Lenart, B Petrik, Z Gaspar, N Kiss-Dala, J Szlavik, ... GeroScience 43 (5), 2205-2213, 2021 | 8 | 2021 |
| Clinical and microbiological outcomes and follow-up of secondary bacterial and fungal infections among critically Ill COVID-19 adult patients treated with and without … BG Szabó, E Czél, I Nagy, D Korózs, B Petrik, B Marosi, Z Gáspár, ... Antibiotics 12 (7), 1196, 2023 | 4 | 2023 |
| Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study B Lakatos, BG Szabó, I Bobek, N Kiss-Dala, Z Gáspár, A Riczu, B Petrik, ... International Journal of Infectious Diseases 125, 233-240, 2022 | 4 | 2022 |
| Hepatitis C-vírus-fertőzés és hepatocarcinogenesis E Berta, A Egresi, A Bacsárdi, Z Gáspár, G Lengyel, K Hagymási Orvosi Hetilap 160 (22), 846-853, 2019 | 4 | 2019 |
| Role of favipiravir in the treatment of adult patients with moderate to severe COVID-19: a single-center, prospective, observational, sequential cohort study from Hungary BG Szabo, KS Lenart, B Petrik, Z Gaspar, Z Balogh, Z Banyai, E Banyasz, ... medRxiv, 2020.11. 26.20238014, 2020 | 3 | 2020 |
| Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences … Z Gáspár, BG Szabó, A Ábrahám, Z Várnai, N Kiss-Dala, J Szlávik, ... Naunyn-schmiedeberg's Archives of Pharmacology 396 (8), 1857-1862, 2023 | 2 | 2023 |
| Az endogén fémionok koncentrációinak változása különböző kórokú, idült májbetegségekben Z Gáspár, A Egresi, G Lengyel, A Blázovics, J Tőke, K Hagymási Orvosi Hetilap 161 (22), 917-923, 2020 | 1 | 2020 |
| Human herpesvirus reactivation and its potential role in the pathogenesis of post-acute sequelae of SARS-CoV-2 infection Z Gáspár, BG Szabó, A Ceglédi, B Lakatos GeroScience, 1-21, 2024 | | 2024 |
| Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated … Z Gáspár, BG Szabó, H Andrikovics, A Ceglédi, M Rajmon, A Ábrahám, ... GeroScience 46 (3), 2863-2877, 2024 | | 2024 |
| Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: experiences from the national … Z GÁSPÁR, BG SZABÓ, A ÁBRAHÁM, Z VÁRNAI, KD Noémi, J SZLÁVIK, ... | | 2022 |
| COVID–19-associated liver enzyme elevation is probably multifactorial Z Gáspár, BG Szabó, N Kiss-Dala, J Szlávik, I Vályi-Nagy, B Lakatos Orvosi hetilap 163 (36), 1415-1421, 2022 | | 2022 |
| A COVID–19-hez kapcsolódó májenzim-emelkedés valószínűleg multifaktoriális eredetű Z Gáspár, BG Szabó, N Kiss-Dala, J Szlávik, I Vályi-Nagy, B Lakatos Orvosi Hetilap 163 (36), 1415-1421, 2022 | | 2022 |
| Role of favipiravir in the treatment of adult patients with moderate to severe COVID2 19: a single-center, prospective, observational, sequential cohort study from Hungary S BG, L KS, B PETRIK, Z GASPAR, Z BALOGH, Z BANYAI, E BANYASZ, ... | | 2020 |
| Changes in endogenous metal element concentrations in various aetiologies of chronic liver disease. Z Gáspár, A Egresi, G Lengyel, A Blázovics, J Tőke, K Hagymási Orvosi Hetilap 161 (22), 917-923, 2020 | | 2020 |
